176 related articles for article (PubMed ID: 30400098)
1. Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.
Babulal GM; Chen S; Williams MM; Trani JF; Bakhshi P; Chao GL; Stout SH; Fagan AM; Benzinger TLS; Holtzman DM; Morris JC; Roe CM
J Alzheimers Dis; 2018; 66(3):1213-1221. PubMed ID: 30400098
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.
Babulal GM; Stout SH; Head D; Holtzman DM; Fagan AM; Morris JC; Roe CM
J Alzheimers Dis; 2017; 58(3):675-680. PubMed ID: 28453487
[TBL] [Abstract][Full Text] [Related]
3. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
5. Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept.
Babulal GM; Johnson A; Fagan AM; Morris JC; Roe CM
J Alzheimers Dis; 2021; 79(3):1009-1014. PubMed ID: 33361605
[TBL] [Abstract][Full Text] [Related]
6. Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
Babulal GM; Chen L; Murphy SA; Carr DB; Morris JC
Neurology; 2024 Jun; 102(12):e209426. PubMed ID: 38776513
[TBL] [Abstract][Full Text] [Related]
7. Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.
Roe CM; Babulal GM; Mishra S; Gordon BA; Stout SH; Ott BR; Carr DB; Ances BM; Morris JC; Benzinger TLS
J Alzheimers Dis; 2018; 61(2):509-513. PubMed ID: 29171997
[TBL] [Abstract][Full Text] [Related]
8. Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.
Roe CM; Barco PP; Head DM; Ghoshal N; Selsor N; Babulal GM; Fierberg R; Vernon EK; Shulman N; Johnson A; Fague S; Xiong C; Grant EA; Campbell A; Ott BR; Holtzman DM; Benzinger TL; Fagan AM; Carr DB; Morris JC
Alzheimer Dis Assoc Disord; 2017; 31(1):69-72. PubMed ID: 27128959
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
11. Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults.
Babulal GM; Roe CM; Stout SH; Rajasekar G; Wisch JK; Benzinger TLS; Morris JC; Ances BM
J Alzheimers Dis; 2020; 74(4):1045-1055. PubMed ID: 32144985
[TBL] [Abstract][Full Text] [Related]
12. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
15. Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease.
Eruysal E; Ravdin L; Zhang C; Kamel H; Iadecola C; Ishii M
J Alzheimers Dis; 2023; 91(3):1073-1083. PubMed ID: 36565112
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
17. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
[TBL] [Abstract][Full Text] [Related]
18. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
19. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]